NasdaqGS - Nasdaq Real Time Price USD
Xilio Therapeutics, Inc. (XLO)
0.9066
+0.0472
+(5.58%)
As of 1:11:42 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 7.4M | 7.4M | 25.1M | 25.6M |
| Low Estimate | 7.4M | 7.4M | 25.1M | 25.6M |
| High Estimate | 7.4M | 7.4M | 25.1M | 25.6M |
| Year Ago Sales | 2.36M | 2.26M | 6.34M | 25.1M |
| Sales Growth (year/est) | 213.96% | 227.00% | 295.65% | 1.99% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.34 | -0.3 | -0.22 | 0.09 |
| EPS Actual | -0.24 | -0.22 | -0.2 | -0.18 |
| Difference | 0.1 | 0.08 | 0.02 | -0.28 |
| Surprise % | 28.54% | 26.15% | 9.09% | -289.47% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| XLO | -- | -- | -- | -- |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Maintains | Raymond James: Outperform to Outperform | 11/8/2024 |
| Reiterates | Chardan Capital: Buy to Buy | 5/30/2023 |
| Reiterates | Chardan Capital: Buy | 5/11/2023 |
| Maintains | Morgan Stanley: Overweight | 1/27/2023 |
| Initiated | Chardan Capital: Buy | 12/21/2022 |
| Maintains | Raymond James: Outperform | 11/10/2022 |
Related Tickers
ABP Abpro Holdings, Inc.
0.3047
+32.25%
CNSP CNS Pharmaceuticals, Inc.
1.2700
-0.78%
KLTO Klotho Neurosciences, Inc.
0.2318
+3.21%
CTMX CytomX Therapeutics, Inc.
2.1350
+5.17%
HCWB HCW Biologics Inc.
8.67
-3.09%
NCNA NuCana plc
0.0480
+9.59%
CABA Cabaletta Bio, Inc.
1.9100
-5.91%
AFMD Affimed N.V.
0.1945
-30.29%
INZY Inozyme Pharma, Inc.
3.9450
-0.13%
QNRX Quoin Pharmaceuticals, Ltd.
7.58
-1.56%